Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Bristol-Myers Squibb
Daiichi Sankyo
AstraZeneca
BicycleTx Limited
AstraZeneca
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Astellas Pharma Inc
G1 Therapeutics, Inc.
Merck Sharp & Dohme LLC
Toray Industries, Inc
University Health Network, Toronto
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins